Selective serotonin reuptake inhibitors: A class review

P and T

Volumn 29, Issue 4, 2004, Pages 234-243

  Valuck, Robert ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ENCAINIDE; ESCITALOPRAM; FLECAINIDE; FLECAINIDE ACETATE; FLUOXETINE; IMIPRAMINE; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MIRTAZAPINE; PAROXETINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE; VERAPAMIL;

AGITATION; ANXIETY DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG ACTIVITY; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; GASTROINTESTINAL DISEASE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; NAUSEA; PARESTHESIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 2142657377     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442.
2. Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States: Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988;45:977-986.
3. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry 1994;151:979-986.
4. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-418.
5. McFarland BH. Cost-effectiveness considerations for managed care systems: Treating depression in primary care. Am J Med 1994;97(Suppl 6A):47S-58S.
6. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(Suppl):1-45.
7. Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice: An update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998;55:1121-1127.
8. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders. III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12(Suppl B):S55-S87.
9. Simon GE, VonKorff M, Wagner EH, Barlow W. Patterns of anti depressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408.
10. Katon W, VonKorff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76.
11. Henk HJ, Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry 1996;53:899-904.
12. Katzelnick DJ, Kobak KA, Greist JH, et al. Effect of primary care treatment of depression on service use by patients with high medical expenditures. Psychiatr Serv 1997;48:59-64.
13. Evans DL, Staab J, Ward H, et al. Depression in the medically ill: Management considerations. Depress Anxiety 1997;4:199-208.
14. Ganzani L, Smith DM, Fenn DS, Lee, MA. Depression and mortality in medically ill older adults. J Am Geriatr Soc 1997;45:307-312.
15. Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care. Pharmacoeconomics 1995;7:284-291.
16. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995;52:850-856.
17. Sleath B, Shih YC. Sociological influences on antidepressant prescribing. Soc Sci Med 2003;56(6):1335-1344.
18. Sclar DA, Robinson LM, Skaer TL, Galin RS. What factors influence prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters. Int J Psychiatry Med 1998;28(4):407-419.
19. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J Psychopharmacol 1998;12(Suppl B):S5-S20.
20. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-108.
21. Effexor® (package insert). Philadelphia, PA; Wyeth Pharmaceuticals, Inc.; 2003.
22. Prozac® (package insert). Indianapolis, IN: Eli Lilly and Company; 2003.
23. Paxil® (package insert). Research Triangle Park, NC: Glaxo-SmithKline; 2003.
24. Zoloft® (package insert). New York, NY: Pfizer Inc.; 2003.
25. Celexa™ (package insert). St Louis, MO: Forest Pharmaceuticals, Inc.; 2002.
26. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993;8:197-202.
27. Beliles K, Stoudemire A. Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 1998;39:S2-S19.
28. Simon GE, VonKorff M, Heiligentstein JH, et al. Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-1902.
29. Crown WH, Treglia M, Meneades L, White A. Long-term costs of treatment for depression: Impact of drug selection and guideline adherence. Value Health 2001;4:295-307.
30. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412.
31. Singletary TS, North DS, Weiss MA, Marman G. A cost-effective approach to the use of selective serotonin reuptake inhibitors in a Veterans Affairs Medical Center. Am J Manag Care 1997;3: 125-129.
32. Nurenberg HG, Hensley PL, Thompson PM, Paine, SS. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors. Psychiatr Serv 1999;50:1351-1353.
33. Express Scripts®. FDA approves Prozac generic. Available at www.express-scripts.com/other/news_views/clinical_news/ clinicalnews-aug01.pdf. Accessed November 17, 2003.
34. Prozac Weekly®. Available at: www.regence.com/trgmedpol/ drugs/dru51.html. Accessed November 17, 2003.
35. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-336.
36. Burke WJ, Kratochvil CJ. Stereoisomers in psychiatry: The case of escitalopram. Primary Care Companion J Clin Psychiatry 2002;4:20-24.
37. Hyttel J, Bøgesø KP, Perreggaard J, Sanchez C. The pharmacological effect of citalopram resides in the (S) - (+) enantiomer. J Neural Transm [Gen Sect] 1992;88:157-160.
38. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102.
39. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-350.
40. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spectrums [MedWorks Media reprint]. 2002;7(Suppl 1):40-44.
41. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug Interactions with newer antidepressants: Role of human cytochrome P450. J Clin Psychiatry 1998;59(Suppl 15):19-27.
42. Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29:1102-1109.
43. Rapaport MH, Bose A, Zheng H, Korotzer A. Escitalopram prevents relapse of depressive episodes. Presented at the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; June 23-27, 2002, Montreal, Quebec, Canada.
44. Lexapro® (package insert). St. Louis, MO: Forest Pharmaceuticals, Inc.; 2002.
45. Valuck RJ. P&T Committee Considerations in the Management of Depression. Round table discussion presented at the third annual P&T Society meeting, May 28, 2003, Chicago.
46. Hamer AM. The latest and greatest on psychotropic medications: The bottom line (slide presentation). Available at: www.cascades east.org. Accessed November 5, 2003.
47. Paxil® CR (package insert). Research Triangle Park, NC: Glaxo-SmithKline; 2003.